Pazopanib and the treatment palette for soft-tissue sarcoma

The Lancet

Volumn 379, Issue 9829, 2012, Pages 1854-1856

  Bramwell, Vivien H C ^a  

^a TOM BAKER CANCER CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PAZOPANIB; PLACEBO;

ADVANCED CANCER; ANOREXIA; ANTIANGIOGENIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG COST; DRUG DOSE REDUCTION; FATIGUE; HUMAN; NAUSEA; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SOFT TISSUE SARCOMA; TREATMENT OUTCOME; VOMITING;

EID: 84861100374     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)60739-9     Document Type: Note

References (12)

1. Verweij J, Baker LH. Future treatment of soft tissue sarcomas will be driven by histological subtype and molecular abberations. Eur J Cancer 2010; 46: 863-68.
2. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1640 patients. J Clin Oncol 2010; 28: 1247-53.
3. Van der Graaf WTA, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012; published online May 16. DOI:10.1016/S0140-6736(12) 60651-5.
4. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001; 357: 1191-94. (Pubitemid 32378696)
5. Van Glabbeke M, Verweij J, Judson I, Nielsen OS, on behalf of the EORTC Soft Tissue and Bone Sarcoma Group. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002; 38: 543-49. (Pubitemid 34185394)
6. Korn EL, Freidlin B, Abrams KS. Overall survival as outcome for randomized clinical trials with effective subsequent therapies. J Clin Oncol 2011; 290: 2439-42.
7. Booth CM, Eisenhauer EA. Progression-free survival: meaningful or simply measurable? J Clin Oncol 2012; 30: 1030-33.
8. Amir E, Seruga B, Martinez-Lopez J, et al. Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs. J Clin Oncol 2011; 29: 2543-49.
9. Meropol NJ, Schrag D, Smith TJ, et al. American Society of Clinical Oncology Guidance statement: the cost of cancer care. J Clin Oncol 2009; 27: 3868-74.
10. Hillner BE, Smith TJ. Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing. J Clin Oncol 2009; 27: 2111-13.
11. Sullivan R, Peppercorn J, Sikora K, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol 2011; 12: 933-80.
12. Mileshkin L, Schofield PE, Jefford M, et al. To tell or not to tell: the community wants to know about expensive anticancer drugs as a potential treatment option. J Clin Oncol 2009; 27: 5830-37.